Devices, kits, and assays are provided for the testing and monitoring of hemoglobin, anemia, glucose-6-phoshate dehydrogenase, and glucose-6-phosphate dehydrogenase deficiency in an individual.

The invention relates to the in vitro and in cellulo detection of the cofactors nicotinamide adenine dinucleotide (NAD) and nicotinamide adenine dinucleotide phosphate (NADP). Provided is a sensor molecule for fluorescence- or luminescence-based detection of a nicotinamide adenine dinucleotide analyte, in particular for detecting the concentrations of NAD.sup.+, NADP.sup.+ and/or the ratios of the concentrations of NAD.sup.+/NADH and NADP.sup.+/NADPH, the sensor comprising (i) a binding protein (BP) for the nicotinamide adenine dinucleotide analyte, the BP being derived from sepiapterin reductase (SPR; EC 1.1.1.153) (ii) an SPR ligand (SPR-L) capable of intramolecular binding to said BP in the presence of the oxidized form of said analyte; and (iii) at least one fluorophore.

A method for quantifying cardiolipin in a sample, comprises the steps of: (1) treating the sample with phospholipase D, glycerol kinase, glycerol-3-phosphate oxidase, and peroxidase and (2) measuring the fluorescence intensity, absorbance, or luminescence intensity of a compound generated in step (1) to quantify cardiolipin using a calibration curve obtained beforehand; and a kit for quantifying cardiolipin comprises phospholipase D, glycerol kinase, glycerol-3-phosphate oxidase, and peroxidase.

There is provided protein biomarkers and methods for their use in diagnosing and treating Inflammatory Bowel Disease (IBD), ulcerative colitis (UC) and Crohn's disease (CD) as well as methods for assessing the severity of the diseases.

Methods for treatment and diagnosis of pervasive developmental disorders in humans are described.

Genetically-encoded volatile synthetic biomarkers and methods for detection of various cancers in a subject are provided. In various aspects, embodiments provide compositions for breath-based cancer detection comprising at least one nucleic acid molecule encoding a synthase that catalyzes production of said volatile organic biomarker. The invention also provides devices, such as an electronic nose device, portable electronic nose device, and/or breath analyzer, for breath-based cancer detection comprising said compositions and at least one analyzer.

A chemiluminescent lateral flow immunoassay method is provided for reducing cross reactions and false positives when detecting protein analytes. The detection method involves a lateral flow immunoassay strip, the strip includes a sample pad, a conjugate pad, a nitrocellulose membrane, and an absorbent pad. The capture antibody of the analyte on the nitrocellulose membrane is used as the test line, and the IgG antibody is used as the control line. The lateral flow immunoassay is performed on the strip by the Au nanoparticle-antibody-horseradish peroxidase-polyethylene glycol (AuNP-Ab-RP-PEG) conjugate to detect the specific analyte. During the detection, the conjugate is prepared in the strip and then added to the analyte for detection, or the conjugate is mixed with the analyte and then added to the strip for detection.

Disclosed are compositions and methods for inactivating one or more enzymes in a biological sample.

Devices and methods for sensing analytes in a solution sample are provided. The device includes a substrate, a conversion component configured to convert the analyte in the sample solution into a metabolite, and an aptamer sensor configured to measure a presence of the metabolite, the aptamer sensor located on the substrate.

The invention relates to a combination of biomarkers and their use in brain injury or mild traumatic brain injury (mTBI) detection.